213 related articles for article (PubMed ID: 28864947)
1. Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis.
Weberpals J; Jansen L; van Herk-Sukel MPP; Kuiper JG; Aarts MJ; Vissers PAJ; Brenner H
Eur J Epidemiol; 2017 Nov; 32(11):1019-1031. PubMed ID: 28864947
[TBL] [Abstract][Full Text] [Related]
2. Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study.
Weberpals J; Jansen L; Haefeli WE; Hoffmeister M; Wolkewitz M; Herk-Sukel MPPV; Vissers PAJ; Brenner H
Sci Rep; 2017 Jun; 7(1):2911. PubMed ID: 28588274
[TBL] [Abstract][Full Text] [Related]
3. Beta blockers and cancer prognosis - The role of immortal time bias: A systematic review and meta-analysis.
Weberpals J; Jansen L; Carr PR; Hoffmeister M; Brenner H
Cancer Treat Rev; 2016 Jun; 47():1-11. PubMed ID: 27179912
[TBL] [Abstract][Full Text] [Related]
4. Pre- and post-diagnostic beta-blocker use and prognosis after colorectal cancer: Results from a population-based study.
Jansen L; Weberpals J; Kuiper JG; Vissers PAJ; Wolkewitz M; Hoffmeister M; Brenner H
Int J Cancer; 2017 Jul; 141(1):62-71. PubMed ID: 28370155
[TBL] [Abstract][Full Text] [Related]
5. Comparative performance of a modified landmark approach when no time of treatment data are available within oncological databases: exemplary cohort study among resected pancreatic cancer patients.
Weberpals J; Jansen L; Silversmit G; Verbeeck J; van der Geest L; Vissers PA; Zadnik V; Brenner H
Clin Epidemiol; 2018; 10():1109-1125. PubMed ID: 30214315
[TBL] [Abstract][Full Text] [Related]
6. β-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study.
Livingstone E; Hollestein LM; van Herk-Sukel MP; van de Poll-Franse L; Nijsten T; Schadendorf D; de Vries E
Eur J Cancer; 2013 Dec; 49(18):3863-71. PubMed ID: 23942335
[TBL] [Abstract][Full Text] [Related]
7. Stage-specific associations between beta blocker use and prognosis after colorectal cancer.
Jansen L; Hoffmeister M; Arndt V; Chang-Claude J; Brenner H
Cancer; 2014 Apr; 120(8):1178-86. PubMed ID: 24415516
[TBL] [Abstract][Full Text] [Related]
8. Cancer net survival on registry data: use of the new unbiased Pohar-Perme estimator and magnitude of the bias with the classical methods.
Roche L; Danieli C; Belot A; Grosclaude P; Bouvier AM; Velten M; Iwaz J; Remontet L; Bossard N
Int J Cancer; 2013 May; 132(10):2359-69. PubMed ID: 22961565
[TBL] [Abstract][Full Text] [Related]
9. Immortal time bias in pharmaco-epidemiology.
Suissa S
Am J Epidemiol; 2008 Feb; 167(4):492-9. PubMed ID: 18056625
[TBL] [Abstract][Full Text] [Related]
10. Impact of immortal person-time and time scale in comparative effectiveness research for medical devices: a case for implantable cardioverter-defibrillators.
Mi X; Hammill BG; Curtis LH; Greiner MA; Setoguchi S
J Clin Epidemiol; 2013 Aug; 66(8 Suppl):S138-44. PubMed ID: 23849148
[TBL] [Abstract][Full Text] [Related]
11. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.
Grytli HH; Fagerland MW; Fosså SD; Taskén KA
Eur Urol; 2014 Mar; 65(3):635-41. PubMed ID: 23351721
[TBL] [Abstract][Full Text] [Related]
12. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
13. Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study.
Holmes S; Griffith EJ; Musto G; Minuk GY
Cancer Epidemiol; 2013 Dec; 37(6):881-5. PubMed ID: 24075077
[TBL] [Abstract][Full Text] [Related]
14. Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy.
Grytli HH; Fagerland MW; Fosså SD; Taskén KA; Håheim LL
Prostate; 2013 Feb; 73(3):250-60. PubMed ID: 22821802
[TBL] [Abstract][Full Text] [Related]
15. Association between perioperative beta blocker use and cancer survival following surgical resection.
Musselman RP; Bennett S; Li W; Mamdani M; Gomes T; van Walraven C; Boushey R; Al-Obeed O; Al-Omran M; Auer RC
Eur J Surg Oncol; 2018 Aug; 44(8):1164-1169. PubMed ID: 29858097
[TBL] [Abstract][Full Text] [Related]
16. The effect of warfarin therapy on breast, colorectal, lung, and prostate cancer survival: a population-based cohort study using the Clinical Practice Research Datalink.
O'Rorke MA; Murray LJ; Hughes CM; Cantwell MM; Cardwell CR
Cancer Causes Control; 2015 Mar; 26(3):355-66. PubMed ID: 25534917
[TBL] [Abstract][Full Text] [Related]
17. Clopidogrel use and cancer-specific mortality: a population-based cohort study of colorectal, breast and prostate cancer patients.
Hicks BM; Murray LJ; Hughes C; Cardwell CR
Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):830-40. PubMed ID: 26017274
[TBL] [Abstract][Full Text] [Related]
18. Socioeconomic variation in cancer survival in the southeastern Netherlands, 1980-1989.
Schrijvers CT; Coebergh JW; van der Heijden LH; Mackenbach JP
Cancer; 1995 Jun; 75(12):2946-53. PubMed ID: 7773946
[TBL] [Abstract][Full Text] [Related]
19. Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer.
Assayag J; Pollak MN; Azoulay L
Eur J Cancer; 2014 Nov; 50(16):2838-45. PubMed ID: 25204805
[TBL] [Abstract][Full Text] [Related]
20. Population-based survival from cancers having a poor prognosis in Mumbai (Bombay), India.
Yeole BB; Kumar AV
Asian Pac J Cancer Prev; 2004; 5(2):175-82. PubMed ID: 15244521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
